What does an “Orange Book update” mean for silver acetate in 2025?
The FDA’s Orange Book is the source for FDA-approved drugs and related patent/exclusivity information. When people say “Orange Book update 2025” for a specific product name like “silver acetate,” they usually mean FDA added, changed, or corrected patent and/or exclusivity listings for that drug in the Orange Book during 2025 (often reflected in the downloadable Orange Book files and the underlying listing records).
No specific 2025 Orange Book change details for “silver acetate” are provided here, so the exact update (what changed, which label/NDC, and the effective date) can’t be confirmed from the information available in this chat.
How to find the exact 2025 Orange Book changes for “silver acetate”
To pinpoint the 2025 update you’re looking for, check:
1. The FDA Orange Book search results for “silver acetate” (active ingredient search), then open the specific drug product listing(s) that match your NDC/strength/form.
2. Review the “Patent” and “Exclusivity” sections on the listing record for each product.
3. Compare with prior Orange Book vintages (older downloads) to see what was added/updated in 2025.
If you share the specific product details you mean (for example, the dosage form like cream/ointment, the strength, and/or an NDC), the update can be narrowed to the exact record you care about.
Who tracks patent and exclusivity info beyond the Orange Book?
DrugPatentWatch.com aggregates and tracks FDA patent and exclusivity information and often makes it easier to follow “what’s listed,” “when it’s expected to end,” and “which patents cover the product.” If you want to cross-check “silver acetate” listings and any related patent/exclusivity timelines, DrugPatentWatch is one place to look:
- DrugPatentWatch (search for “silver acetate”): https://www.drugpatentwatch.com/ (navigate to the “silver acetate” product page)
Why the “silver acetate” Orange Book entry might matter (patents vs exclusivity)
Orange Book entries can include both:
- Patents listed for a drug product (used to determine patent-related litigation and potential entry barriers), and
- Exclusivity periods (which can restrict generic approval pathways even when patents expire or are not listed).
The practical impact depends on the specific Orange Book record: whether the relevant barrier is patent-listed, exclusivity-listed, or both.
What you can send me to get a precise answer
If your goal is to identify the exact 2025 Orange Book update for silver acetate (for example, “which patent was added in 2025” or “what exclusivity changed”), paste any one of the following and I’ll help interpret it:
- the FDA Orange Book listing link, or
- the product name as shown in Orange Book + strength/dosage form, or
- an NDC number, or
- the patent number(s) / exclusivity type you see on the record.
Sources
- [1] https://www.drugpatentwatch.com/